RT Journal Article
SR Electronic
T1 Silybin Is Metabolized by Cytochrome P450 2C8 in Vitro
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 2035
OP 2039
DO 10.1124/dmd.107.016410
VO 35
IS 11
A1 Petra Jančová
A1 Eva Anzenbacherová
A1 Barbora Papoušková
A1 Karel Lemr
A1 Pavla Lužná
A1 Alena Veinlichová
A1 Pavel Anzenbacher
A1 Vilím Šimánek
YR 2007
UL http://dmd.aspetjournals.org/content/35/11/2035.abstract
AB Silybin (a flavonolignan, the main component of silymarin, an extract from the seeds of Silybum marianum) has been used to date mostly as a hepatoprotectant. However, it also has other interesting activities, e.g., anticancer and hypocholesterolemic effects. It is also known that silybin can inhibit the activities of the cytochrome P450 (P450) enzymes. In this study, a weak interaction of silybin with human microsomal CYP2E1, 2A6, 2B6, 2C19, and 2D6 (IC50 ≥ 250 μM) was found; a moderate inhibition was observed for CYP1A2 and 2C8. The most prominent inhibition effect was found with CYP3A4 and CYP2C9 (IC50 ≤ 50 μM). Using mass spectometry detection, production of O-demethylated (the main metabolite) as well as hydroxylated derivatives of silybin formed by P450 enzymes was detected. The effect of different P450 inhibitors on the formation of O-demethylated product was also studied. In particular, a relatively specific inhibitor of CYP2C8 (quercetin) markedly inhibited the formation of this metabolite. With the help of recombinant enzymes (bactosomes), it was confirmed that the CYP2C8 enzyme is responsible for the reaction leading to O-demethylated silybin. The American Society for Pharmacology and Experimental Therapeutics